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OBJECTIVE — Hypoglycemia in young children with type 1 diabetes is an acute complica-
tionofintensiveinsulintherapyandiscommonlyobservedintheabsenceofsignsorsymptoms.
The effect of intensive treatment and patient age on sympathoadrenal responses has not been
established in youth with type 1 diabetes because of difﬁculties in testing procedures.
RESEARCH DESIGN AND METHODS — We developed a standardized inpatient con-
tinuous subcutaneous insulin infusion protocol to produce a progressive fall in plasma glucose
concentrations in insulin pump–treated patients. Plasma glucose and counterregulatory hor-
mone concentrations were measured in 14 young children (3 to 8 years, A1C 7.7  0.6%) vs.
14 adolescents (12 to 18 years, A1C 7.6  0.8%).
RESULTS — Plasma glucose decreased to similar nadir concentrations in the two groups.
Fouryoungchildrenandfouradolescentsneverhadanepinephrineresponse.Inthefouryoung
children and ﬁve adolescents who had a modest epinephrine response, this only occurred when
plasma glucose fell to 60 mg/dl. In evaluating symptom scores, 29% of parents of young
children felt that their child looked hypoglycemic, even at the lowest plasma glucose concen-
trations. Adolescents were better able to detect symptoms of hypoglycemia. In comparison with
our data, epinephrine response to hypoglycemia in 14 nondiabetic adolescents studied at the
Children’s Hospital of Pittsburgh was higher.
CONCLUSIONS — These data suggest that even young children and adolescents with type
1 diabetes are prone to develop hypoglycemia-associated autonomic failure regardless of dura-
tion. Whether these abnormalities can be reversed using continuous glucose monitoring and
closed-loop insulin delivery systems awaits further study.
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S
evere hypoglycemia is a life-
threatening complication of inten-
sive therapy of type 1 diabetes,
especially in youth. In the Diabetes Con-
trol and Complications Trial, adolescents
had a higher rate of severe hypoglycemia
than adults (1). Young children are at
even greater risk (2) and pose a particular
therapeutic dilemma, because recurrent
episodes of hypoglycemia may have ad-
verse effects on brain development, and
anecdotal reports from parents indicate
that hypoglycemic events are commonly
observed in this age-group in the absence
of any signs or symptoms. In nondiabetic
children hypoglycemia triggers counter-
regulatory responses that include in-
creases in plasma glucagon and
epinephrine concentrations. In nondia-
betic adolescents and in conventionally
treated adolescents with poorly con-
trolled type 1 diabetes, the plasma glu-
cose threshold that stimulates an
epinephrine response has been reported
to be higher and the rise in epinephrine
levelsisgreaterthaninnondiabeticadults
(3). Because glucagon responses to hypo-
glycemia are lost early in the disease (4),
an intact plasma epinephrine response is
critical in patients with type 1 diabetes.
In adults with type 1 diabetes, the ep-
isodes of mild hypoglycemia that accom-
pany intensive treatment induce a defect
in sympathoadrenal responses that has
been termed hypoglycemia-associated
autonomic failure (5–8). Whether inten-
sive treatment causes similar defects in
youth with type 1 diabetes has not been
wellstudied,inpartbecauseofdifﬁculties
in performing controlled hypoglycemia
clamps in children.
We developed a continuous subcuta-
neous insulin infusion protocol to pro-
duce a progressive fall in plasma glucose
in insulin pump–treated youth with well-
controlled type 1 diabetes. Counterregu-
latory hormone concentrations were
measured sequentially to compare the
plasma glucose threshold for and magni-
tude of these hormone responses in
young children versus adolescents. Al-
though not strictly comparable, we also
reporttheepinephrineresponsestoasim-
ilar degree of hypoglycemia in nondia-
betic adolescents to provide a frame of
reference to judge responses to hypogly-
cemia in the type 1 diabetic subjects.
RESEARCH DESIGN AND
METHODS— Subjectswithtype1di-
abetes were studied at the ﬁve DirecNet
clinical centers. A data and safety moni-
toring board and institutional review
boards at each center approved the study
protocol and consent and assent forms. A
parent or guardian and each subject aged
7yearsgavewrittenconsentandassent,
respectively.
Eligibility criteria
Eligibility criteria for type 1 diabetic sub-
jects were 1)a g e3t o8 years or 12 to
18 years, 2) duration of type 1 diabetes
of1year,3)useofaninsulinpump,and
4) A1C 10.0% (DCA2000 analyzer;
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napolis,IN).Exclusioncriteriaincludeda
severe hypoglycemic event resulting in
seizure or loss of consciousness in the last
month, use of systemic or inhaled corti-
costeroids in the last month, or cystic
ﬁbrosis.
Study procedures
Subjects with type 1 diabetes were admit-
ted to the research center on the evening
before the study. An intravenous catheter
wasinsertedinanarmveinforbloodsam-
pling. Glucose measurements were made
using the One Touch Ultra meter at bed-
time, 12:00 A.M., 3:00 A.M., 6:00 A.M., and
7:00 A.M. Oral carbohydrates were given
topreventlowglucoselevelswiththegoal
of having the glucose values 110 mg/dl
at 8:00 A.M. If glucose levels were high,
and it was predicted that it would take a
long time for the glucose level to drop to
110 mg/dl, small insulin correction doses
were given.
At the start of the test, a bolus dose of
insulin equal to 1 hour of the subject’s
basal rate at that time was given, and the
basal insulin infusion rate was increased
by 25–50%. The basal insulin rate was
increased further, and additional insulin
doses were given, if needed, to achieve a
gradual decline in plasma glucose.
Bloodsamplesformeterglucosemea-
surements were obtained every 15 min
until the glucose value was 100 mg/dl
and at 5- to 10-min intervals thereafter,
until the end of the study. Blood samples
were obtained for determination of glu-
cose, epinephrine, norepinephrine, corti-
sol, glucagon, and growth hormone at
baseline, when the meter glucose was
between 95 and 110 mg/dl (in dupli-
cate) and then 90, 80, 70, and
60 mg/dl. Once the glucose level fell
to 60 mg/dl, intravenous glucose was
given, the basal rate was returned to nor-
mal, and breakfast was eaten. An addi-
tional blood sample was collected for
glucose and hormone concentrations 15
min after treatment with glucose.
At each blood sampling time, parents
were asked whether their child “looked
low,” and adolescents were asked
whether they “felt low.” Parents and ado-
lescents were masked to the meter glu-
cose, and they ranked their response on a
4-point scale where 0/1 denoted “Not at
all”/“Very little,” 2 denoted “Some,” and 3
denoted “Very much.”
Laboratory procedures
Blood samples were frozen before ship-
ping. Glucagon, cortisol, growth hor-
mone, and glucose concentrations were
measuredattheDirecNetCentralLabora-
tory (University of Minnesota). Glucagon
was measured by a radioimmunoassay
(Linco Research, St. Charles, MO) with
theprimaryantibodyfromguineapigand
the secondary antibody from goat. The
lower limit of detection was 20 pg/ml (6
pmol/l). Coefﬁcients of variation (CVs)
were 6.5–8.8% on three control samples.
Cortisol was assayed with a competitive
chemiluminescence assay (Bayer Advia
Centaur; Bayer HealthCare, Diagnostics
Division, Tarrytown, NY), using a poly-
clonal rabbit antibody and a mouse
monoclonal antibody coupled with para-
magnetic particles. The lower limit of de-
tection was 0.5 g/dl (14 nmol/l). CVs
were 11–12% on two control samples.
Growth hormone was measured by a
sandwichchemiluminescenceassay(DPC
Immulite; Diagnostic Products Corpora-
tion, Los Angeles, CA). Monoclonal
mouse antibody was coated on the bead
with a rabbit polyclonal antibody in the
reagent. The lower limit of detection was
0.1 ng/ml (4 pmol/l). CVs were 5.9–
9.1%.Glucosedeterminationsweremade
using a hexokinase enzymatic method in
the laboratory (9,10) and measured by
the meter at the bedside (5).
Epinephrine and norepinephrine
concentrations were measured at the
Mayo Clinic Laboratory (Rochester, MN)
using a reverse-phase (C18) high-
pressure liquid chromatography column
to separate norepinephrine and epineph-
rine, which were detected coulometri-
cally, using an ESA Coulochem II
instrument. The lower limit of detection
was10pg/ml(0.06nmol/land55pmol/l,
respectively). CVs were 7–11% and
6–7% on two control samples. Catechol-
amine samples were collected in EDTA
tubes and frozen immediately. This
method was determined to not cause any
difference in values versus when samples
were collected in EDTA-sodium bisulﬁte
tubes.
Nondiabetic subjects
Studies in 14 nondiabetic adolescents be-
tween 12 and 17 years of age (14.8  2.1
years, mean  SD) were performed at the
Children’s Hospital of Pittsburgh (Pitts-
burgh, PA) under a protocol approved by
its institutional review board between
1999 and 2002. Subjects were studied in
the morning after an overnight fast. Two
intravenous catheters, one for blood sam-
pling and one for glucose and insulin in-
fusion, were inserted in the nondominant
arm.Afterbaselinebloodsamplesforglu-
cose and catecholamines were obtained,
an intravenous insulin infusion was be-
gun at a rate of 0.1 unit   kg
1   h
1
throughoutthestudy.Glucoselevelswere
maintained at 103  6 mg/dl for 60 min
by a variable rate infusion of 20% dex-
trose. Subsequently, glucose levels were
allowedtofallto644mg/dlbydecreas-
ing the intravenous glucose infusion over
a 20- to 25-min period. The hypoglyce-
mic nadir was maintained for 60 min.
Blood was withdrawn every 15 min for
measurement of plasma epinephrine
concentrations.
Epinephrine concentrations in these
samples were originally measured using a
high-pressure liquid chromatographic
method on either the LCEC capsule N-46
BioanalyticalSystem(Lafayette,IN)orthe
ESA system (ESA, Chelmsford, MA). Ex-
tra plasma was frozen and stored at
70°C. A subset (n  18) of these sam-
ples was reassayed in the DirecNet Cen-
tral Laboratory. The 25th, 50th, and 75th
quartile levels for the original analysis
were 96, 174, and 312 pg/ml and the cor-
responding values from the DirecNet lab-
oratory were 10, 73, and 186 pg/ml. In
the nine samples obtained during the 1-h
hypoglycemic phase of the Pittsburgh
study, the original median peak plasma
epinephrineconcentrationwas312pg/ml
(range 126–848) vs. 186 pg/ml (range
10–758) on reanalysis in the DirecNet
Central Laboratory.
Statistical methods
Based on the study by Jones et al. (11), 50
subjects(25ineachofthetwoage-groups
withtype1diabetes)wereestimatedtobe
needed to detect, with 90% power and a
type 1 error rate of 5%, a difference be-
tween the two groups in the peak epi-
nephrine response, assuming a true mean
differenceof300pg/mlwithanSDof306
pg/ml.Thestudywasdiscontinuedaftera
preplanned interim analysis, when it was
determined that a signiﬁcant mean differ-
ence would be unachievable, even with a
much larger sample size.
The comparison of the diabetes dura-
tioninthetwoage-groupswasperformed
using a two-sample t test. Analyses in-
volving plasma glucose concentrations
usedlaboratoryratherthanmeterglucose
values. Time intervals between the 90
mg/dl and postglucose treatment blood
samplingswerecomparedusingapairedt
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stimulated a counterregulatory hormone
response was deﬁned as the point at
which the hormone concentration was
3 SD above baseline (with the SD based
on the duplicate blood samples at base-
line). The 3-SD limits were 26 pg/ml for
epinephrine, 44 pg/ml for norepineph-
rine, 0.83 g/dl for cortisol, 1.2 ng/ml for
growthhormone,and16pg/mlforgluca-
gon.Theproportionsofsubjectswhohad
hormone responses in each age-group
were compared using Fisher’s exact test.
Group comparisons of the change in hor-
mone concentration from baseline to
peak were performed using an ANCOVA
model based on van der Waerden normal
scoresandadjustedforthecorresponding
baseline value.
The study was completed by 30 sub-
jects with type 1 diabetes. One subject in
each age-group was not included in the
analysis because of blood sampling prob-
lems. Because the Pittsburgh study used a
one-step hypoglycemic clamp, lowering
glucose in one step from 100 to 60
mg/dl, plasma epinephrine responses in
this study were used only to describe the
magnitude of the plasma epinephrine re-
sponses in nondiabetic subjects.
RESULTS— Primary analysis in-
cluded 14 young children (4–7 years old;
duration of diabetes 3.3  1.1 years) and
14adolescents(12–17yearsold;duration
of diabetes 6.6  3.4 years, P  0.003)
with type 1 diabetes. Of the young chil-
dren, 21% were female and 86% were
Caucasian vs. 43 and 100%, respectively,
for adolescents. Mean A1C was 7.7 
0.6% in young children and 7.6  0.8%
in adolescents. The 14 nondiabetic ado-
lescents studied in Pittsburgh were 29%
female and 93% Caucasian. A1C for all
these subjects was 6.1%.
Plasma glucose during hypoglycemia
testing in type 1 diabetic subjects
Individual baseline and nadir plasma glu-
cose concentrations in the patients with
type 1 diabetes are shown in Fig. 1.
Plasma glucose was reduced gradually to
ameannadirconcentrationof61mg/dlin
the young children and 59 mg/dl in ado-
lescents.Nadirglucoseconcentrationwas
60 mg/dl in 8 of 14 subjects in each
group and between 60 and 70 mg/dl in
5subjectsineachgroup.Inonlyonechild
and one adolescent was the nadir 70
mg/dl (i.e., 73 and 74 mg/dl). The mean
time interval between 90 mg/dl and
postglucose treatment blood sampling
tended to be longer in adolescents than in
younger children (71 vs. 53 min, P 
0.06).
Counterregulatory hormone
responses in type 1 diabetic subjects
Individual baseline and peak plasma epi-
nephrine concentrations in type 1 dia-
betic subjects are also shown in Fig. 1. As
summarizedinTable1,4of14subjectsin
each age-group never had an epinephrine
response, despite nadir plasma glucose
concentrations that ranged between 56
and 67 mg/dl in the young children and
58 and 74 mg/dl in the adolescents. Four
young children and ﬁve adolescents did
notmanifestanepinephrineresponseun-
tilplasmaglucosefellto60mg/dl.Only
two children and no adolescents had an
Figure 1—Plasma glucose concentrations from baseline to nadir and epinephrine concentrations from baseline to peak in young children (A) and
adolescents (B). Each line and symbol combination represents a unique subject in the glucose and epinephrine plots.
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epinephrine release. Nine of 14 young
children and 8 of 14 adolescents never
had a norepinephrine response to hypo-
glycemia (Table 1). Two adolescents had
a high glucose threshold for norepineph-
rine response.
Median, 25th, and 75th percentile of
baseline and peak plasma concentrations
of epinephrine, norepinephrine, cortisol,
growth hormone, and glucagon were not
different in young children and adoles-
cents(Table2).Inaddition,thechangein
hormone concentrations and the number
of subjects who had a response in each
group were not different. In contrast,
the median plasma epinephrine con-
centrations in nondiabetic subjects rose
from 77 to 582 pg/ml in response to
hypoglycemia.
Symptom scores
Table 3 shows the responses to the state-
ment “I feel like my glucose is low” by the
adolescents and by parents of the young
children to the statement “My child looks
low.” Only a small fraction of parents felt
thattheirchildlookedhypoglycemiceven
at the lowest plasma glucose concentra-
tions. In contrast, the percentage of ado-
lescentswhoreportedmorethanminimal
symptoms of hypoglycemia increased
when glucose levels fell to 70 mg/dl.
CONCLUSIONS — The principal
aim of this study was to compare the epi-
nephrine responses to hypoglycemia in
youngchildrenandadolescentswithtype
1 diabetes. We hypothesized that, despite
ashorterdurationofdiabetes,theglucose
threshold and magnitude of the epineph-
rine response would be lower in the
young children. The study protocol al-
lowedustolowerplasmaglucoseconcen-
trations to the same nadir and to estimate
the glucose concentrations that stimu-
lated epinephrine and other counterregu-
latory hormone responses between the
two groups. The nadir glucose tended to
be achieved faster in young children, but
the rate of the fall in glucose has not been
shown to affect counterregulatory hor-
mone responses to hypoglycemia (12).
Ourmostconcerningﬁndingwasthat
29% of subjects in both age-groups failed
to stimulate any epinephrine response,
despite in most cases, reaching a blood
glucose level 60 mg/dl, and plasma epi-
nephrine concentrations only rose mod-
estly in those who did. An even greater
percentage of subjects in both groups
failed to mount a plasma norepinephrine
or cortisol response and the glucagon re-
sponse to hypoglycemia was virtually
absent.
We had postulated that the plasma
epinephrine response in adolescents with
type 1 diabetes would be similar to the
response that had been reported in non-
diabetic subjects and reduced by up to
50% in young children with type 1 dia-
betes. Previous studies of plasma epi-
Table 1—Plasma glucose concentrations at epinephrine and norepinephrine response
Plasma glucose at
time of ﬁrst
response*
Epinephrine response* Norepinephrine response*
Young children Adolescents Young children Adolescents
n 14 14 14 14
90 mg/dl† 2002
80 to 90 mg/dl 0002
70 to 80 mg/dl 1110
60 to 70 mg/dl 3421
60 mg/dl 4521
Never responded‡ 4‡ 4‡ 9§ 8§
*The hormone response was deﬁned as 3 SDs above baseline. †The maximum laboratory glucose concen-
trationtriggeringepinephrineresponsewas96mg/dl(fromayoungchildwithabaselinevalueof125mg/dl)
and the triggering norepinephrine response was 116 mg/dl (from an adolescent with a baseline value of 125
mg/dl).‡Thenadirglucosevaluesrangedfrom56to67mg/dlinyoungchildrenand58to74inadolescents.
§The nadir glucose values ranged from 54 to 68 mg/dl in young children and 46 to 69 in adolescents.
Table 2—Counterregulatory hormone concentrations by age-group
Young children Adolescents
Epinephrine
n 14 14
Baseline (pg/ml) 47 (39, 56) 27 (25, 37)
Peak (pg/ml) 82 (68, 115) 71 (41, 229)
Change (pg/ml)* 36 (23, 68) 50 (16, 182)
Increased 3 SDs† 10 (71) 10 (71)
Norepinephrine
n 14 14
Baseline (pg/ml) 120 (107, 128) 153 (108, 226)
Peak (pg/ml) 138 (122, 186) 219 (169, 271)
Change (pg/ml)* 31 (9, 64) 40 (26, 76)
Increased 3 SDs† 5 (36) 6 (43)
Cortisol
n 14 14
Baseline (g/ml) 9.4 (8.2, 10.9) 12.7 (10.1, 14.1)
Peak (g/ml) 10.1 (8.5, 11.7) 12.0 (9.8, 14.4)
Change (g/ml)* 0.5 (1.4, 1.9) 0.1 (0.6, 0.8)
Increased 3 SDs† 5 (36) 3 (21)
Growth hormone
n 14 14
Baseline (ng/ml) 1.4 (0.5, 4.2) 2.0 (0.3, 9.7)
Peak (ng/ml) 5.2 (2.2, 13.9) 6.7 (2.6, 18.8)
Change (ng/ml)* 1.6 (0.3, 9.4) 2.5 (0.4, 17.3)
Increased 3 SDs† 9 (64) 9 (64)
Glucagon
n 13‡ 14
Baseline (pg/ml) 42 (33, 50) 48 (32, 57)
Peak (pg/ml) 42 (36, 43) 50 (31, 57)
Change (pg/ml)* 3( 4, 2) 1( 2, 9)
Increased 3 SDs† 1 (8) 1 (7)
Data are median (25th, 75th percentile) or n (%). Total n  28. *Deﬁned as peak minus baseline. †3 SDs
described in RESEARCH DESIGN AND METHODS. ‡Samples for glucagon were drawn only at baseline and at meter
glucose value 60 mg/dl. One subject was missing the end draw.
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performed 15–20 years ago (11,12)
demonstrated that in nondiabetic chil-
dren aged 8–18 years, plasma epineph-
rine concentrations rose to 600 pg/ml,
whenplasmaglucosewasloweredto60
mg/dl. Youth with poorly controlled type
1 diabetes (mean A1C 15.1%) had an
even higher threshold for release of epi-
nephrine, but the peak epinephrine re-
sponse was similar to that in nondiabetic
subjects (11). These adolescents with
poorly controlled diabetes did not have
hypoglycemia unawareness as conﬁrmed
by their symptom scores, which were
similartothoseofthenondiabeticcontrol
subjects. In contrast, 29% of our adoles-
centsreportedfewornosymptomsofhy-
poglycemia with plasma glucose 60
mg/dl.
Because the epinephrine responses
observed in our adolescents with type 1
diabetes were so dramatically different
from those reported previously in dia-
betic and nondiabetic subjects (11,12),
we were concerned that changes in assay
methods over the years were responsible
for the marked discrepancy. Fortunately,
frozen samples from hypoglycemia
studies performed in Pittsburgh in non-
diabetic adolescents, who showed epi-
nephrine responses that were similar to
those in the previous studies (11,12),
wereavailableforreanalysis.Eventhough
the samples from Pittsburgh showed evi-
dence of loss of epinephrine concentra-
tions after 6–9 years of storage, the assay
resultsweresimilarenoughtotheassayat
the DirecNet laboratory to indicate that
the marked blunting of the epinephrine
responses in our subjects could not sim-
ply be due to differences in assay meth-
ods. However, the difference in the
method of developing hypoglycemia in
our study versus that in the older studies
(slower versus rapid fall in plasma glu-
cose) adds another note of caution in in-
terpreting these results.
A number of elegant studies in adults
with and without type 1 diabetes have
demonstrated that recent antecedent hy-
poglycemia impairs the counterregula-
tory hormone responses to subsequent
hypoglycemia and increases the risk for
severe hypoglycemic events (6–8). Me-
ticulous prevention of hypoglycemia is
able to at least partially reverse impaired
counterregulatory hormone responses to
hypoglycemia(13).Clinicalresearchcen-
ter–based exercise studies and outpatient
continuous glucose monitoring studies
conducted by DirecNet have shown that
asymptomatic biochemical hypoglycemia
is very common in youth with type 1 di-
abetes (14–16). Unfortunately, it appears
fromtheresultsofthisstudythatchildren
are also prone to develop hypoglycemia-
associatedautonomicfailure,asobservedin
adults (5). In addition, as illustrated by the
symptom assessment carried out in this
study, the risk of severe hypoglycemia may
be increased in young children because
their parents are unable to recognize glu-
cose levels falling into a dangerous range in
the absence of a meter glucose measure-
ment. Clearly, further studies are needed to
clarify how often and to what extent coun-
terregulatory defense mechanisms are im-
paired in children and adolescents with
type 1 diabetes and whether these abnor-
malities can be reversed with intensive dia-
betes management using continuous
glucosemonitoringandclosed-loopinsulin
delivery systems.
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